Holen Sie sich die Stockscreener-App
8.77
0.23%
0.02
Handel nachbörslich:
8.76
-0.010
-0.11%
Sage Therapeutics Inc Aktie (SAGE) Neueste Nachrichten
What drives Sage Therapeutics Inc. stock priceUnbelievable profit margins - Autocar Professional
What analysts say about Sage Therapeutics Inc. stockFree Investment Community - Autocar Professional
Sage Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com
Is Sage Therapeutics Inc. a good long term investmentFree Daily Trading Room Entry - jammulinksnews.com
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Sage Therapeutics (NASDAQ:SAGE) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Stock Price Crosses Above 50 Day Moving AverageHere's Why - MarketBeat
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Sage Therapeutics, Inc. - 富途牛牛
Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, - openPR.com
Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Marinus Pharmac, Pfizer, UCB Biopharma, Rafa Laboratories, Sage Therapeutics - The Globe and Mail
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Sage Therapeutics (NASDAQ:SAGE) Downgraded to Hold Rating by Scotiabank - MarketBeat
SAGE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Sage Therapeutics, Inc. is Fair to Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect - ACCESS Newswire
43,638 Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE) Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Reduce" from Analysts - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Rating Lowered to “Hold” at Scotiabank - Defense World
Sage Therapeutics Announces Workforce Reductions Following Recent Acquisition Plans - geneonline.com
Postpartum Depression Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, SAGE, OLO on Behalf of Shareholders - Morningstar
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock - Nasdaq
SAGE: Scotiabank Downgrades Sage Therapeutics with Price Target Adjustment | SAGE Stock News - GuruFocus
Scotiabank Downgrades SAGE Therapeutics to Sector Perform From Sector Outperform, Adjusts Price Target to $9.20 From $12 - MarketScreener
Wealth Enhancement Advisory Services LLC Takes $347,000 Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Scotiabank Downgrades Sage Therapeutics (SAGE) - MSN
Sage Therapeutics (NASDAQ:SAGE) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of “Hold” from Analysts - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE - Eastern Progress
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What Makes Sage Therapeutics (SAGE) a New Buy Stock - Yahoo Finance
Sage to lay off most staff amid Supernus buyout - Yahoo Finance
Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGE - ACCESS Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Phathom Pharmaceuticals Strengthens Leadership: Sage Therapeutics Legal Head Joins GI-focused Biotech as CLO - Stock Titan
SAGE: Baird Adjusts Price Target on Sage Therapeutics | SAGE Stock News - GuruFocus
Canaccord Genuity Group Issues Positive Forecast for Sage Therapeutics (NASDAQ:SAGE) Stock Price - MarketBeat
Needham & Company LLC Reiterates "Hold" Rating for Sage Therapeutics (NASDAQ:SAGE) - MarketBeat
4.91%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):